KKR & Co Inc vs Medtronic PLC — how do they compare? KKR & Co Inc trades at $97.44 (market cap $87.07B), while Medtronic PLC trades at $82.6 (market cap $106.61B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| KKR | MDT | |
|---|---|---|
Market Cap | $87.07B | $106.61B |
Sector | Financials | Health |
52-Week High | $152.16 | $105.35 |
52-Week Low | $83.88 | $73.75 |
Enterprise Value | $12.59B | $125.36B |
Dividend Yield | 0.77% | 3.46% |
Signals from Pluang's Aura AI — not financial advice
KKR trades at $96.72, down 4.19% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $1.39, beating estimates, and maintains strong analyst support with 24 buy ratings. Recent developments include a $1.3 billion renewable energy joint venture in South Korea and the acquisition of EDF Power Solutions' North American operations for $4.2 billion, highlighting strategic expansion.
The outlook for KKR is positive, supported by robust deal activity and a favorable analyst consensus price target of $124.33. Key risks include execution of large acquisitions and market sensitivity to interest rate changes. Revenue is projected to grow to $20.4 billion in 2026, with net income margin improving to 14.51%, offering potential upside if operational targets are met.
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →